Everything you need to win Variant Bio — in one platform.
Who to reach, what to say, and why now on Variant Bio — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on Variant Bio — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
The decision-maker’s email and mobile — dial in-browser.
Variant Bio Announces $50 Million Collaboration with Novo Nordisk for Developing Drugs from Indigenous Population Genetic Data
Jan 07, 2025•over 1 year ago
Contract Type
partnership
SeattleBiotechnology
Description
Variant Bio, a Seattle-based drug company, revealed a $50 million partnership with Novo Nordisk to create drugs for metabolic disorders using genetic data from Indigenous populations in nine countries or territories, including the Māori. The company plans to share a portion of the funds with the communities it worked with and provide resulting medicines at affordable prices to those communities.
Company Information
Company
Variant Bio
Location
188 E Blaine St, Suite 126
Seattle, Washington, United States
About
Variant Bio is developing therapies that will improve global health by studying the genes of people who are outliers for medically relevant traits.
SeattleBiotechnology